Novel Integrative Methods for Gene Discovery Associated With Head and Neck Squamous Cell Carcinoma Development

Smith, Ian; Mithani, Suhail K.; Liu, Chunyan; Chang, Steven S.; Begum, Shahnaz; Dhara, Mousiumi; Westra, William; Sidranksy, David; Califano, Joseph A.

doi:10.1001/archoto.2009.43

Cited by 11 publications

(11 citation statements)

References 36 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the role and potential involvement of the DLEC1 gene in HNSCC remains unknown. In the current study, we observed down-regulation in DLEC1 mRNA expression in 63 of the 97 (64.9%) fresh HNSCC tumor tissue samples supporting the report by Smith et al (2009). However, DLEC1 mRNA was increased in 33% of tumor tissue samples compared to normal tissues.…”

Section: Discussionsupporting

confidence: 89%

“…Zhang et al, 2010;Kwong et al, 2006Kwong et al, , 2007Ying et al, 2009;Smith et al, 2009). In 2009, Smith et al (2009) performed an integrative gene discovery approach to identify the consensus cancer coding sequences in deleted and amplified chromosomal regions in HNSCC. The DLEC1 gene has been identified as one of the putative consensus cancer coding sequences.…”

Section: Discussionmentioning

confidence: 99%

“…There is only one report in the literature investigating expression of the DLEC1 gene in HNSCC (Smith et al, 2009). This report has shown that DLEC1 expression was repressed at the transcriptional level in 3 of 4 HNSCC tumor tissues.…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma

Seven

Yavuz

Kılıç

et al. 2015

Gene

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma

Seven

Yavuz

Kılıç

et al. 2015

Gene

View full text Add to dashboard Cite

“…However, the DLEC1 methylation status was correlated with survival in Japanese lung cancer patients. DLEC1 is a candidate tumor-suppressor gene found in multiple cancer types (3)(4)(5)7,15,16). DLEC1 suppresses tumor growth or reduces the invasiveness of cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…Alleic loss of chromosome 3p is one of the most frequent and earliest documented events in lung cancer with a wide range of 3p mutations (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26), suggesting the presence of multiple tumor-suppressor genes on 3p (1)(2)(3). the chromosome locus 3p22.3 is a 'hot spot' for chromosomal aberrations and loss of heterozygosity in cancers, including lung cancer (4,5).…”

Section: Introductionmentioning

confidence: 99%

Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients

Sasaki

Hikosaka²,

Kawano³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. the incidence of chromosome 3p gene alterations is one of the most frequent and earliest documented events in lung cancer. this study aimed to investigate promoter methylation in the deleted in lung and esophageal cancer 1 (DLEC1) gene, as well as the p16 and CDH1 genes in Japanese lung cancer cases. the methylation status of the promoter regions of DLEC1, p16 and CDH1 was investigated using methylation-specific PCR. The findings were compared to the clinicopathological features of lung cancer. Methylation-specific PCR showed that the DLEC1 promoter region was methylated in 65 out of 116 (56%) lung cancers. Patients with DLEC1-methylated cancer were associated with a significantly worse prognosis than those with unmethylated cancer (p=0.0368; hazard ratio=1.83). the p16 methylation status correlated with squamous histology (p=0.03) and smoking status (never smoker vs. smoker; p=0.0122). Patients with p16 ummethylated cancer harbored more EGFR mutations (p=0.0071). the CDH1 promoter region was hypermethylated in 65 out of 118 (55.1%) lung cancer cases. However, the CDH1 methylation status was not associated with the clinicopathological characteristics of the lung cancer types. p16 and CDH1 methylation status did not correlate with survival in the lung cancer patients. thus, in our Japanese cohort, the methylation status of the DLEC1 gene was a marker of poor prognosis independent of stage.

show abstract

Mass spectrometry‐based clinical proteomics: Head‐and‐neck cancer biomarkers and drug‐targets discovery

Matta

Ralhan

DeSouza

et al. 2010

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Mass spectrometry (MS)-based proteomics is a rapidly developing technology for both qualitative and quantitative analyses of proteins, and investigations into protein posttranslational modifications, subcellular localization, and interactions. Recent advancements in MS have made tremendous impact on the throughput and comprehensiveness of cancer proteomics, paving the way to unraveling deregulated cellular pathway networks in human malignancies. In turn, this knowledge is rapidly being translated into the discovery of novel potential cancer markers (PCMs) and targets for molecular therapeutics. Head-and-neck cancer is one of the most morbid human malignancies with an overall poor prognosis and severely compromised quality of life. Early detection and novel therapeutic strategies are urgently needed for more effective disease management. The characterizations of protein profiles of head-and-neck cancers and non-malignant tissues, with unprecedented sensitivity and precision, are providing technology platforms for identification of novel PCMs and drug targets. Importantly, low-abundance proteins are being identified and characterized, not only from the tumor tissues, but also from bodily fluids (plasma, saliva, and urine) in a high-throughput and unbiased manner. This review is a critical appraisal of recent advances in MS-based proteomic technologies and platforms for facilitating the discovery of biomarkers and novel drug targets in head-and-neck cancer. A major challenge in the discovery and verification of these cancer biomarkers is the typically limited availability of well-characterized and adequately stored clinical samples in tumor and sera banks, collected using recommended procedures, and with detailed information on clinical, pathological parameters, and follow-up. Most biomarker discovery studies use limited number of clinical samples and verification of cancer markers in large number of samples is beyond the scope of a single laboratory. The validation of these potential markers in large sample cohorts in multicentric studies is needed for their translation from the bench to the bedside.

show abstract

Novel Integrative Methods for Gene Discovery Associated With Head and Neck Squamous Cell Carcinoma Development

Abstract: With the advent of high-throughput techniques to study cancer genetics, novel comparisons of large data sets using integrative methods may elucidate genetic alterations in HNSCC cancer.

Cited by 11 publications

References 36 publications

DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma

DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma

Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients

Mass spectrometry‐based clinical proteomics: Head‐and‐neck cancer biomarkers and drug‐targets discovery

Contact Info

Product

Resources

About